cimetidine has been researched along with Osteosarcoma in 1 studies
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Cimetidine and the antioxidant N-acetylcysteine (NAC) significantly inhibited the in vitro growth inhibition of cisplatin in cells originating from the kidney, but not in SOSN2 osteosarcoma cells." | 3.76 | Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. ( Katsuda, H; Katsura, H; Miyamoto, K; Nagata, N; Sai, Y; Waki, Y; Yamashita, M; Yu, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katsuda, H | 1 |
| Yamashita, M | 1 |
| Katsura, H | 1 |
| Yu, J | 1 |
| Waki, Y | 1 |
| Nagata, N | 1 |
| Sai, Y | 1 |
| Miyamoto, K | 1 |
1 other study available for cimetidine and Osteosarcoma
| Article | Year |
|---|---|
Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line; Cell Line, Tumor; Cimetid | 2010 |